Autoimmune myasthenia gravis
- PMID: 8380423
- DOI: 10.1080/21548331.1993.11442741
Autoimmune myasthenia gravis
Erratum in
- Hosp Pract (Off Ed) 1993 Mar 15;28(3):12
Abstract
The evident defect in this disease is postsynaptic dysfunction due to anti-acetylcholine receptor antibodies. The postsynaptic membrane is simplified, the number of acetylcholine receptors is reduced, and neuromuscular transmission is impaired. Antiacetylcholinesterase drugs still play a role in management. Newer options include prednisone, azathioprine, and cyclosporine.
Publication types
MeSH terms
Substances
LinkOut - more resources
Medical